Cargando…

A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode

PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition....

Descripción completa

Detalles Bibliográficos
Autores principales: Camargo, Cristina Pires, Weschenfelder, Rafael Hori Nagamine, da Fonseca, Guilherme Moreira, Sousa, Alexandre Agostinho da Cruz, Gemperli, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412997/
https://www.ncbi.nlm.nih.gov/pubmed/32813772
http://dx.doi.org/10.1590/s0102-865020200070000004
_version_ 1783568718254571520
author Camargo, Cristina Pires
Weschenfelder, Rafael Hori Nagamine
da Fonseca, Guilherme Moreira
Sousa, Alexandre Agostinho da Cruz
Gemperli, Rolf
author_facet Camargo, Cristina Pires
Weschenfelder, Rafael Hori Nagamine
da Fonseca, Guilherme Moreira
Sousa, Alexandre Agostinho da Cruz
Gemperli, Rolf
author_sort Camargo, Cristina Pires
collection PubMed
description PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition. METHODS: We analyzed 20 Wistar rats, age eight-weeks, weight between 200g-250g. All animals received an intravenous injection of Streptozotocin (55mg/kg weight). On the 15th day after D induction, the animals were divided into two groups: Group I – animals receiving a single daily dose of fast-acting insulin (FAIG) NPH (1UI,SC) for partial glycemic control, and Group II - animals receiving slow-acting insulin(SAIG) twice a week. We measured glycemia, weight, and adverse events every week during two months. RESULTS: Of the total of animals analyzed in the study, three animals died in the FAIG and two animals died in the SAIG. Regarding the glycemic level, results were 339.5 ± 125.4mg/dL (95CI 302.3402 to 376.6842) in the FAIG, and 367.8 ± 66.1mg/dL (95IC 333.7607 to 401.8978) in the SAIG. There was no difference between groups as to weight during the study. CONCLUSION: The use of slow-acting-insulin is not inferior to the use of fast-acting-insulin in the management of partially insulin-controlled moderate diabetes in rats.
format Online
Article
Text
id pubmed-7412997
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
record_format MEDLINE/PubMed
spelling pubmed-74129972020-08-25 A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode Camargo, Cristina Pires Weschenfelder, Rafael Hori Nagamine da Fonseca, Guilherme Moreira Sousa, Alexandre Agostinho da Cruz Gemperli, Rolf Acta Cir Bras Original Article PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition. METHODS: We analyzed 20 Wistar rats, age eight-weeks, weight between 200g-250g. All animals received an intravenous injection of Streptozotocin (55mg/kg weight). On the 15th day after D induction, the animals were divided into two groups: Group I – animals receiving a single daily dose of fast-acting insulin (FAIG) NPH (1UI,SC) for partial glycemic control, and Group II - animals receiving slow-acting insulin(SAIG) twice a week. We measured glycemia, weight, and adverse events every week during two months. RESULTS: Of the total of animals analyzed in the study, three animals died in the FAIG and two animals died in the SAIG. Regarding the glycemic level, results were 339.5 ± 125.4mg/dL (95CI 302.3402 to 376.6842) in the FAIG, and 367.8 ± 66.1mg/dL (95IC 333.7607 to 401.8978) in the SAIG. There was no difference between groups as to weight during the study. CONCLUSION: The use of slow-acting-insulin is not inferior to the use of fast-acting-insulin in the management of partially insulin-controlled moderate diabetes in rats. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020-08-05 /pmc/articles/PMC7412997/ /pubmed/32813772 http://dx.doi.org/10.1590/s0102-865020200070000004 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Camargo, Cristina Pires
Weschenfelder, Rafael Hori Nagamine
da Fonseca, Guilherme Moreira
Sousa, Alexandre Agostinho da Cruz
Gemperli, Rolf
A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title_full A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title_fullStr A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title_full_unstemmed A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title_short A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
title_sort non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412997/
https://www.ncbi.nlm.nih.gov/pubmed/32813772
http://dx.doi.org/10.1590/s0102-865020200070000004
work_keys_str_mv AT camargocristinapires anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT weschenfelderrafaelhorinagamine anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT dafonsecaguilhermemoreira anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT sousaalexandreagostinhodacruz anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT gemperlirolf anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT camargocristinapires noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT weschenfelderrafaelhorinagamine noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT dafonsecaguilhermemoreira noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT sousaalexandreagostinhodacruz noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode
AT gemperlirolf noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode